Ocular adverse events with immune checkpoint inhibitors

PURPOSE: To quantify the risk of ocular adverse events with immune checkpoint inhibitors (ICIs) as reported to the Food and Drug Administration (FDA). METHODS: Disproportionality analysis using data from U.S. FDA's Adverse Events Reporting System (FAERS) database 2003 to 2018. Data from pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Tony, Maberley, David A., Etminan, Mahyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742617/
https://www.ncbi.nlm.nih.gov/pubmed/31528768
http://dx.doi.org/10.1016/j.joco.2019.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742617/
https://www.ncbi.nlm.nih.gov/pubmed/31528768
http://dx.doi.org/10.1016/j.joco.2019.05.002

Ejemplares similares